Table 5.
Initial imaging modalities and major findings that led to further examinations.
| Initial imaging modalities and major findings | Symptomatic group (n = 372) | Asymptomatic group (n = 172) | P value |
|---|---|---|---|
| US, n | 125 | 71 | |
| Pancreatic tumors, n (%) | 114 (91.2) | 51 (71.8) | < 0.001 |
| Indirect findings without tumor detection, n (%) | 11 (8.8) | 20 (28.2) | |
| CT, n | 236 | 76 | |
| Pancreatic tumors, n (%) | 232 (98.3) | 65 (85.5) | < 0.001 |
| Indirect findings without tumor detection, n (%) | 4 (1.7) | 11 (14.5) | |
| MRI, n | 5 | 13 | |
| Pancreatic tumors, n (%) | 2 (40.0) | 5 (38.5) | 1.00 |
| Indirect findings without tumor detection, n (%) | 3 (60.0) | 8 (61.5) | |
| PET, n | 5 | 9 | |
| Pancreatic tumors with FDG accumulation, n (%) | 5 (100) | 9 (100) | N/A |
| EUS, n | 1 | 3 | |
| Pancreatic tumors, n (%) | 1 (100) | 3 (100) | N/A |
| Indirect findings without tumor detection, n (%) | 0 (0) | 0 (0) | |
| All imaging modalities, n | 372 | 172 | |
| Pancreatic tumors, n (%) | 354 (95.2) | 133 (77.3) | < 0.001 |
| Indirect findings without tumor detection, n (%) | 18 (4.8) | 39 (22.7) |
CT computed tomography, US ultrasonography, MRI magnetic resonance imaging, PET positron emission tomography, FDG fluorodeoxyglucose, EUS endoscopic ultrasonography, N/A not available.